Belsomra (Suvorexant) Patent Expiration, LOE Window & CMS Spending
Belsomra (Suvorexant) by Merck & Co.: FDA Orange Book core substance LOE 2029-11-20 (last listed 2033-05-29), 0 AB generics, $170.7M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Merck & Co. |
| FDA Application & Pathway | N204569 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2029-11-20 |
| Last Listed Patent or Exclusivity Date | 2033-05-29 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $170.7M |
| 2024 Medicare Part D Spend | $150.2M |
| 2024 Medicaid Spend | $20.5M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.